Immunotherapy for head and neck squamous cell carcinoma.
Immunotherapy for head and neck squamous cell carcinoma.
复制标题
头颈鳞状细胞癌的免疫治疗。
作者：
Fuereder T
在过去的几年里，免疫肿瘤学已经发展成为一种新的有前途的癌症治疗策略。靶向程序性死亡受体1/程序性死亡配体1（PD-1/PDL-1）和PDL-2之间相互作用的免疫检查点抑制剂（如派姆单抗或纳武单抗）最近已被批准用于治疗各种恶性肿瘤，目前正在进行头颈部鳞状细胞癌（HNSCC）的III期临床试验。从这些试验中获得的数据表明，在该患者人群中具有显著的活性，同时具有良好的安全性和毒性特征。这篇综述文章侧重于分子背景，概述了HNSCC中检查点抑制剂的当前临床数据，并指出了未来的挑战，例如需要为这些新型化合物提供适当的生物标志物。
Over the past years immuno-oncology has evolved and become a novel promising strategy for cancer therapy. Immune checkpoint inhibitors such as pembrolizumab or nivolumab, which target the interaction between programmed death receptor 1/programmed death ligand 1 (PD-1/PDL-1) and PDL-2, have been recently approved for the treatment of various malignancies and are currently being investigated in clinical phase III trials for head and neck squamous cell carcinoma (HNSCC). Data available from these trials indicate substantial activity accompanied by a favorable safety and toxicity profile in this patient population. This review article focuses on the molecular background, gives an overview of current clinical data of checkpoint inhibitors in HNSCC, and points out future challenges such as the need for appropriate biomarkers for these novel compounds.